Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT
Otto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks · 2026
Read Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT by Otto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624878.txt.
Description
Otto Simonsson and five co-authors report the health harms people attribute to psychedelic drugs in a national survey, in this 2026 study. Substances such as psilocybin, LSD, and MDMA have shown promise for mental illness in careful trials. Two stronger, shorter-acting compounds, ibogaine and 5-MeO-DMT, have shown early promise too. But trial patients are screened and supervised, while real-world users vary in dose, purity, and setting, and often mix drugs.
The team used a nationally representative survey of United States adults to record bad health outcomes people linked to recent use of each of the five substances. As laws loosen, public messages need real-world harm data rather than trial data alone. The study supplies that missing picture: how often things go wrong outside the clinic, and for which substances. Such evidence can guide safer policy and honest warnings.
Catalog record
| CREATOR | Otto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |